Fernando de la Cuesta

Dr. Fernando de la Cuesta

Department of Pharmacology and Therapeutics, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Kidney International
Verified
Journal Article
Closed access
MPMaría Posada-Ayala
María Posada-Ayala
IZIrene Zubiri
Irene Zubiri
Marta Martín-LorenzoMarta Martín-Lorenzo
Marta Martín-Lorenzo
ASAroa Sanz-Maroto
Aroa Sanz-Maroto
DMDolores Molero
Dolores Molero
Gloria Alvarez-LlamasGloria Alvarez-Llamas
Gloria Alvarez-Llamas

1 January 2014 in Journal of Proteomics
Verified
Journal Article
Closed access
IZIrene Zubiri
Irene Zubiri
MPMaría Posada-Ayala
María Posada-Ayala
ASAroa Sanz-Maroto
Aroa Sanz-Maroto
ECEnrique Calvo
Enrique Calvo
Marta Martín-LorenzoMarta Martín-Lorenzo
Marta Martín-Lorenzo
Gloria Alvarez-LlamasGloria Alvarez-Llamas
Gloria Alvarez-Llamas

2 January 2011 in BioMed Research International
Verified
Journal Article
Open access
PDF file
María G BarderasMaría G Barderas
María G Barderas
CLCarlos M Laborde
Carlos M Laborde
MPMaría Posada-Ayala
María Posada-Ayala
Fernando de la CuestaFernando de la Cuesta
Fernando de la Cuesta
IZIrene Zubiri
Irene Zubiri
Gloria Alvarez-LlamasGloria Alvarez-Llamas
Gloria Alvarez-Llamas
Metabolomics involves the identification and quantification of metabolites present in a biological system. Three different approaches can be used: metabolomic fingerprinting, metabolic profiling, and metabolic footprinting, in order to evaluate the clinical course of a disease, patient recovery, changes in response to surgical intervention or pharmacological treatment, as well as other associated features. Characteristic patterns of metabolites can be revealed that broaden our understanding of a particular disorder. In the present paper, common strategies and analytical techniques used in metabolomic studies are reviewed, particularly with reference to the cardiovascular field.

1 November 2015 in Translational Research
Verified
Journal Article
Closed access
IZIrene Zubiri
Irene Zubiri
MPMaría Posada-Ayala
María Posada-Ayala
ABAlberto Benito-Martin
Alberto Benito-Martin
AMAroa S. Maroto
Aroa S. Maroto
Marta Martín-LorenzoMarta Martín-Lorenzo
Marta Martín-Lorenzo
Gloria Alvarez-LlamasGloria Alvarez-Llamas
Gloria Alvarez-Llamas

1 April 2011 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
Fernando de la CuestaFernando de la Cuesta
Fernando de la Cuesta
Gloria Alvarez-LlamasGloria Alvarez-Llamas
Gloria Alvarez-Llamas
AMAroa S. Maroto
Aroa S. Maroto
ADAlicia Donado
Alicia Donado
IZIrene Zubiri
Irene Zubiri
FVFernando Vivanco
Fernando Vivanco
Coronary atherosclerosis still represents the major cause of mortality in western societies. Initiation of atherosclerosis occurs within the intima, where major histological and molecular changes are produced during pathogenesis. So far, proteomic analysis of the atherome plaque has been mainly tackled by the analysis of the entire tissue, which may be a challenging approach because of the great complexity of this sample in terms of layers and cell type composition. Based on this, we aimed to study the intimal proteome from the human atherosclerotic coronary artery. For this purpose, we analyzed the intimal layer from human atherosclerotic coronaries, which were isolated by laser microdissection, and compared with those from preatherosclerotic coronary and radial arteries, using a two-dimensional Differential-In-Gel-Electrophoresis (DIGE) approach. Results have pointed out 13 proteins to be altered (seven up-regulated and six down-regulated), which are implicated in the migrative capacity of vascular smooth muscle cells, extracellular matrix composition, coagulation, apoptosis, heat shock response, and intraplaque hemorrhage deposition. Among these, three proteins (annexin 4, myosin regulatory light 2, smooth muscle isoform, and ferritin light chain) constitute novel atherosclerotic coronary intima proteins, because they were not previously identified at this human coronary layer. For this reason, these novel proteins were validated by immunohistochemistry, together with hemoglobin and vimentin, in an independent cohort of arteries.

1 January 2022 in Aging and disease
Verified
Journal Article
Open access
ARAlejandra Romero
Alejandra Romero
PDPilar Dongil
Pilar Dongil
IVInés Valencia
Inés Valencia
SVSusana Vallejo
Susana Vallejo
ÁHÁlvaro San Hipólito-Luengo
Álvaro San Hipólito-Luengo
CPConcepcion Peiro
Concepcion Peiro
The clinical relevance of IL-1β in chronic inflammation underlying atherosclerosis has been reinforced by recent evidence associating pharmacological inhibition of the cytokine with lower cardiovascular risk. Previously, we have demonstrated a direct involvement of IL-1β in endothelial senescence. Therefore, this can be a key mechanism contributing to the sterile inflammatory milieu associated with aging, termed inflammaging. In the present study, we have evaluated whether a positive feedback of IL-1β in the NLRP3 inflammasome via NF-κB could promote human endothelial senescence in vitro and murine endothelial dysfunction in vivo. Our results indicate that the NLRP3 inflammasome is pivotal in mediating the detrimental effects of IL-1β, showing that auto-activation is a crucial feature boosting endothelial cell senescence in vitro, which is paralleled by vascular dysfunction in vivo. Hence, the inhibitor of NLRP3 inflammasome assembly, MCC 950, was able to disrupt the aforementioned positive loop, thus alleviating inflammation, cell senescence and vascular dysfunction. Besides, we explored alternative NLRP3 inflammasome inhibitory agents such as the RAS heptapeptide Ang-(1-7) and the anti-aging protein klotho, both of which demonstrated protective effects in vitro and in vivo. Altogether, our results highlight a fundamental role for the hereby described NLRP3 inflammasome/IL-1β positive feedback loop in stress-induced inflammaging and the associated vascular dysfunction, additionally providing evidence of a potential therapeutic use of MCC 950, Ang-(1-7) and recombinant klotho to block this loop and its deleterious effects.